08:36 AM EDT, 08/02/2024 (MT Newswires) -- Twist Bioscience ( TWST ) reported a fiscal Q3 loss Friday of $1.47 per diluted share, widening from a loss of $1.01 a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $0.77.

Revenue for the quarter ended June 30 was $81.5 million, up from $63.7 million a year earlier.

Analysts surveyed by Capital IQ expected $77.4 million.

The company said it now expects fiscal Q4 revenue of $82 million to $83 million, compared with its previous forecast of $77 million to $80 million. Analysts surveyed by Capital IQ expect $79.9 million.

For fiscal year 2024, the company now expects revenue of $310 million to $311 million, compared with its previous guidance of $300 million to $304 million. Analysts polled by Capital IQ expect $303.8 million.

Twist shares rose by more than 2% in premarket trading.

Price: 52.93, Change: -0.12, Percent Change: -0.23